Centralyze is venture studio that identifies, builds and funds breakthrough Australian and APAC startups commercialising innovative research in medical devices and therapeutic technologies
Engineering the Future of Life Sciences
From AI-predicted opportunity to global commercial exit — our studio fund model powers the entire venture lifecycle
Key Stats
Biotech ventures built
0
+
Commercial exits
0
Equity participation
25-
26
%
Capital gains tax (ESVCLP structure)
0
%
Target IRR: p.a.
>
25
%
Why Centralyze?
A. Precision Sourcing with BiblioEngine
Centralyze’s proprietary bibliometric AI tool mines PubMed, ClinicalTrials.gov and other sources to:
- Identify new disease characterisations and repurposing opportunities
- Map patent gaps and future therapeutic demand
- Enable early signal detection, well before market consensus
B. Embedded Regulatory & Clinical Expertise
Portfolio companies benefit from built-in medical, TGA regulatory, and commercial strategy via a proven team of MDs, PhDs, and biotech executives.
C. Global Collaborative Edge (Web3.0 Platform)
All assets leverage our secure virtual IP collaboration environment — reducing development cost, connecting cross-border licensing partners, and enabling fractionalised IP.
D. Aligned Fund Model
- ESVCLP-registered (Early Stage Venture Capital Limited Partnership)
- Tax-free returns for wholesale clients
- Structured exits: licensing, pharma acquisition, or early IPO
- Minimum investment: $250k (flexible)
Unfair Advantages for the Next Era of Biotech